Last reviewed · How we verify
Zodiac Produtos Farmaceuticos S.A. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Meloxicam and Glucosamine | Meloxicam and Glucosamine | phase 3 | NSAID + nutraceutical combination | COX-2 (meloxicam); cartilage matrix precursor (glucosamine) | Rheumatology / Orthopedics |
Therapeutic area mix
- Rheumatology / Orthopedics · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Zodiac Produtos Farmaceuticos S.A.:
- Zodiac Produtos Farmaceuticos S.A. pipeline updates — RSS
- Zodiac Produtos Farmaceuticos S.A. pipeline updates — Atom
- Zodiac Produtos Farmaceuticos S.A. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Zodiac Produtos Farmaceuticos S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zodiac-produtos-farmaceuticos-s-a. Accessed 2026-05-17.